SG11201506014VA - Remote loading of sparingly water-soluble drugs into liposomes - Google Patents

Remote loading of sparingly water-soluble drugs into liposomes

Info

Publication number
SG11201506014VA
SG11201506014VA SG11201506014VA SG11201506014VA SG11201506014VA SG 11201506014V A SG11201506014V A SG 11201506014VA SG 11201506014V A SG11201506014V A SG 11201506014VA SG 11201506014V A SG11201506014V A SG 11201506014VA SG 11201506014V A SG11201506014V A SG 11201506014VA
Authority
SG
Singapore
Prior art keywords
liposomes
soluble drugs
sparingly water
remote loading
loading
Prior art date
Application number
SG11201506014VA
Other languages
English (en)
Inventor
Mark E Hayes
Charles O Noble
Francis C Szoka Jr
Original Assignee
Zoneone Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoneone Pharma Inc filed Critical Zoneone Pharma Inc
Publication of SG11201506014VA publication Critical patent/SG11201506014VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/08—Simple coacervation, i.e. addition of highly hydrophilic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201506014VA 2013-02-01 2014-02-03 Remote loading of sparingly water-soluble drugs into liposomes SG11201506014VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759914P 2013-02-01 2013-02-01
PCT/US2014/014480 WO2014121211A2 (en) 2013-02-01 2014-02-03 Remote loading of sparingly water-soluble drugs into liposomes

Publications (1)

Publication Number Publication Date
SG11201506014VA true SG11201506014VA (en) 2015-08-28

Family

ID=51259399

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201506014VA SG11201506014VA (en) 2013-02-01 2014-02-03 Remote loading of sparingly water-soluble drugs into liposomes
SG10201706239VA SG10201706239VA (en) 2013-02-01 2014-02-03 Remote loading of sparingly water-soluble drugs into liposomes

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201706239VA SG10201706239VA (en) 2013-02-01 2014-02-03 Remote loading of sparingly water-soluble drugs into liposomes

Country Status (15)

Country Link
US (6) US20140220111A1 (de)
EP (3) EP4309657A3 (de)
KR (2) KR102554628B1 (de)
CN (1) CN105163720B (de)
AU (2) AU2014212096B2 (de)
CA (1) CA2899882C (de)
DK (2) DK2950784T3 (de)
ES (2) ES2877084T3 (de)
FI (1) FI3922241T3 (de)
HR (1) HRP20231522T1 (de)
PT (1) PT2950784T (de)
SG (2) SG11201506014VA (de)
SI (1) SI3922241T1 (de)
WO (1) WO2014121211A2 (de)
ZA (2) ZA201506400B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636376B2 (en) * 2012-09-11 2017-05-02 Innopharma, Inc. Stable compositions of peptide epoxy ketones
FI3922241T3 (fi) 2013-02-01 2023-11-28 Celator Pharmaceuticals Inc Niukasti liukoisten lääkkeiden etälataus liposomeihin
US10220095B2 (en) 2013-03-15 2019-03-05 Taiwan Liposome Company, Ltd Controlled drug release liposome compositions and methods thereof
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
IL311537A (en) 2014-01-28 2024-05-01 Mayo Found Medical Education & Res Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US10004759B2 (en) 2014-08-04 2018-06-26 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles
WO2016025559A1 (en) * 2014-08-13 2016-02-18 Zoneone Pharma, Inc. Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems
US20170231910A1 (en) * 2014-08-13 2017-08-17 Mark E. Hayes Pharmaceutical formulations of chelating agents as a metal removal treatment system
CN105497871A (zh) * 2014-09-25 2016-04-20 深圳翰宇药业股份有限公司 一种卡非佐米药物的脂质体冻干组合物及其制备方法
US20160220710A1 (en) * 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Compositions and methods for delivering pharmaceutical agents
CA2977827C (en) 2015-03-19 2023-10-17 University Of Connecticut Systems and methods for continuous manufacturing of liposomal drug formulations
KR101730399B1 (ko) * 2015-04-13 2017-04-27 영남대학교 산학협력단 악시티닙을 포함하는 약물 전달체 및 이의 제조방법
CA3024951A1 (en) * 2015-05-26 2016-12-01 Comfort Care For Animals Llc Liposome loading
CN106317188A (zh) * 2015-06-18 2017-01-11 重庆医药工业研究院有限责任公司 一种制备卡非佐米无定型物的方法
KR101723784B1 (ko) * 2015-08-17 2017-04-07 가톨릭대학교 산학협력단 ｃ－ΜΕΤ 억제제를 유효성분으로 포함하는 독소루비신 및 광역학 치료 항암 효과 증진용 약학 조성물
US20170065520A1 (en) * 2015-09-09 2017-03-09 Manli International Ltd Stable liposomal formulations of rapamycin and rapamycin derivatives for treating cancer
US20170119666A1 (en) * 2015-10-29 2017-05-04 Peregrine Ophthalmic PTE LTD. Stable liposomal formulations of alpha 2 adrenergic agonists for ocular delivery
KR20220101204A (ko) 2016-03-02 2022-07-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
CN105784453B (zh) * 2016-03-16 2018-04-13 吉林省水产科学研究院 鱼肉中阿维菌素和伊维菌素残留检测的前处理方法
TWI754659B (zh) * 2016-08-08 2022-02-11 台灣微脂體股份有限公司 用於製備含有弱酸性劑之微脂體組合物的傳輸載體、方法及套組
JPWO2018124033A1 (ja) * 2016-12-26 2019-11-14 富士フイルム株式会社 脂質粒子組成物および医薬組成物
RU2765736C2 (ru) * 2017-01-18 2022-02-02 Темасек Лайф Сайенсиз Лаборатори Лимитед Гиперстабилизированные липосомы, повышающие направленное таргетирование митотических клеток
CN108853507A (zh) * 2017-05-11 2018-11-23 复旦大学 一种抗肿瘤的增效药物组合物及其制备方法和用途
CN108703971B (zh) * 2017-07-11 2023-04-07 南华大学 抗hiv药物可比司它用于制备抗血栓药物的用途
CN109364025A (zh) * 2017-11-17 2019-02-22 和龙 脂质体组合物、其制备方法及其应用
KR102046355B1 (ko) * 2018-02-08 2019-11-19 국방과학연구소 피하주사용 피소스티그민의 서방출성 리포좀 제제 및 이의 제조 방법
US20190275102A1 (en) * 2018-03-06 2019-09-12 Cadila Healthcare Limited Sterile injectable composition comprising carfilzomib
EP3784213B1 (de) * 2018-04-23 2023-09-06 InspirMed Corp. Inhalierbare liposomale zubereitung mit verzögerter freisetzung zur behandlung von lungenerkrankungen
US20210378961A1 (en) * 2018-07-24 2021-12-09 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
EP3829539A4 (de) * 2018-08-02 2022-05-04 Taiwan Liposome Company, Ltd. Zusammensetzungen mit verzögerter freisetzung mit einem therapeutischen mittel zur behandlung von depressionen oder angstzuständen sowie deren verwendungen
WO2020033195A1 (en) * 2018-08-08 2020-02-13 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
JP7482487B2 (ja) * 2018-09-13 2024-05-14 タイワン リポソーム カンパニー リミテッド 鎮静薬を含む徐放性医薬組成物およびその使用
WO2020102323A1 (en) * 2018-11-14 2020-05-22 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof
CN109528654B (zh) * 2018-12-14 2021-04-23 沈阳药科大学 一种盐酸伊立替康和盐酸阿霉素共载脂质体及其制备方法
TW202108137A (zh) * 2019-05-14 2021-03-01 台灣微脂體股份有限公司 用於治療肺部疾病之可吸入的支氣管擴張劑緩釋組成物
JP2023522323A (ja) * 2020-04-15 2023-05-30 カシーヴ バイオサイエンシズ，リミテッド・ライアビリティ・カンパニー そのまま安定に希釈するためのカルフィルゾミブ製剤
WO2021239134A1 (zh) 2020-05-29 2021-12-02 江苏恒瑞医药股份有限公司 含有乙二胺四乙酸或其盐的艾日布林或其可药用盐脂质体
WO2022124898A1 (en) * 2020-12-09 2022-06-16 Erasmus University Medical Center Rotterdam Auristatin-loaded liposomes and uses thereof.
CN112851789B (zh) * 2021-02-04 2022-10-18 大理大学 一种脑靶向hiv进入抑制剂多肽及其应用
CN115006532A (zh) * 2021-03-05 2022-09-06 广州医科大学 蛋白酶体抑制剂的应用
WO2023029041A1 (zh) * 2021-09-06 2023-03-09 北京茵诺医药科技有限公司 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法
CN114344303B (zh) * 2022-01-13 2023-05-09 江苏海洋大学 一种新型精神药物固体分散体及制备方法和应用
CN114832113B (zh) * 2022-03-22 2023-06-20 重庆医科大学 疏水药物-马来酰亚胺衍生物及其主动载药脂质体和应用
WO2024010886A2 (en) * 2022-07-07 2024-01-11 Nanostar Pharmaceuticals Ltd. Multilamellar vesicle drug formulation
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
CN116027000B (zh) * 2022-12-30 2024-05-17 南京明捷生物医药检测有限公司 一种检测白蛋白脂质体纳米粒体外溶出度的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932657A (en) 1973-11-12 1976-01-13 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome encapsulation of chelating agents
US4016290A (en) 1973-11-12 1977-04-05 The United States Of America As Represented By The United States Energy Research And Development Administration Method of encapsulating polyaminopolycarboxylic acid chelating agents in liposomes
US4310506A (en) 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
NZ201010A (en) 1981-06-19 1986-02-21 Ciba Geigy Ag The treatment of inflammation diseases using desferrioxamine
US5043166A (en) 1987-01-09 1991-08-27 Hadasit Medical Research, Inc. Liposome/anthraquinone drug composition and method
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5534241A (en) 1993-07-23 1996-07-09 Torchilin; Vladimir P. Amphipathic polychelating compounds and methods of use
DE4341472A1 (de) * 1993-12-02 1995-06-08 Schering Ag Verfahren zur Erhöhung der Stabilität von hydrophile Wirkstoffe enthaltenden Liposomensuspensionen
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
WO1996032930A1 (en) 1995-04-18 1996-10-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US6447800B2 (en) 1996-01-18 2002-09-10 The University Of British Columbia Method of loading preformed liposomes using ethanol
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US5827532A (en) * 1997-01-31 1998-10-27 The Reagents Of The University Of California Method for loading lipsomes with ionizable phosphorylated hydrophobic compounds, pharmaceutical preparations and a method for administering the preparations
US7112338B2 (en) 1997-03-12 2006-09-26 The Regents Of The University Of California Cationic liposome delivery of taxanes to angiogenic blood vessels
AU754559B2 (en) 1998-08-12 2002-11-21 New York University Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
MXPA02006121A (es) 1999-12-30 2004-08-23 Judith K Gwathemy Sistema de suministro de formador de quelatos de hierro.
US8029795B2 (en) 1999-12-30 2011-10-04 Gwathmey, Inc. Targeted iron chelator delivery system
US7485320B2 (en) * 2000-09-25 2009-02-03 Industrial Technology Research Institute Liposome for incorporating large amounts of hydrophobic substances
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
JP2005505602A (ja) * 2001-09-06 2005-02-24 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 予め規定された放出プロファイルを有するリポソーム調剤の製造方法
US20050208119A1 (en) 2004-03-18 2005-09-22 Takemoto Arnold C Encapsulated oral chelating preparations
CA2821167C (en) * 2004-05-03 2016-06-28 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
US8658203B2 (en) * 2004-05-03 2014-02-25 Merrimack Pharmaceuticals, Inc. Liposomes useful for drug delivery to the brain
EP1855669A4 (de) 2005-01-28 2010-07-07 Bc Cancer Agency Liposomale zusammensetzungen zur parenteralen zuführung von agentien
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
US20120021042A1 (en) * 2005-09-15 2012-01-26 Steffen Panzner Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances
US20080107747A1 (en) * 2006-10-23 2008-05-08 Roederer Joy E Pain relief composition
JP2010536874A (ja) * 2007-08-21 2010-12-02 アルザ・コーポレーシヨン ボロン酸化合物をインビボ投与するためのリポソーム組成物
US20090196917A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
US8481526B2 (en) * 2009-03-25 2013-07-09 Bausch & Lomb Incorporated Fluoroquinolone carboxylic acid molecular crystals
ME02518B (de) * 2009-03-30 2017-02-20 Eisai R&D Man Co Ltd Liposomenzusammensetzung
EP2480208A1 (de) * 2009-09-23 2012-08-01 Indu Javeri Verfahren zur herstellung von liposomen
CA2776925C (en) 2009-10-26 2018-07-24 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt
US20110178287A1 (en) * 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
EP2531175A2 (de) * 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomen mit amphipathischen wirkstoffen und herstellungsverfahren dafür
EP2680820B1 (de) * 2011-03-01 2022-11-02 2-BBB Medicines B.V. Fortschrittliches, aktives liposomales laden von schwer wasserlöslichen substanzen
FI3922241T3 (fi) 2013-02-01 2023-11-28 Celator Pharmaceuticals Inc Niukasti liukoisten lääkkeiden etälataus liposomeihin
WO2014153192A1 (en) 2013-03-14 2014-09-25 Zoneone Pharma, Inc. Pharmaceutical formulations of chelating agents as a metal removal treatment system
US10004759B2 (en) * 2014-08-04 2018-06-26 Zoneone Pharma, Inc. Remote loading of sparingly water-soluble drugs into lipid vesicles

Also Published As

Publication number Publication date
US10722467B2 (en) 2020-07-28
EP3922241B1 (de) 2023-11-15
EP4309657A3 (de) 2024-02-28
DK2950784T3 (da) 2021-07-05
US20190314282A1 (en) 2019-10-17
AU2019200756A1 (en) 2019-02-21
US20170202776A1 (en) 2017-07-20
KR20150139500A (ko) 2015-12-11
CN105163720A (zh) 2015-12-16
CA2899882A1 (en) 2014-08-07
CA2899882C (en) 2023-12-12
EP3922241A1 (de) 2021-12-15
AU2014212096A1 (en) 2015-09-17
WO2014121211A2 (en) 2014-08-07
US20140220110A1 (en) 2014-08-07
US20140220111A1 (en) 2014-08-07
EP2950784B1 (de) 2021-04-07
US10507182B2 (en) 2019-12-17
AU2014212096B2 (en) 2018-11-08
PT2950784T (pt) 2021-06-30
SG10201706239VA (en) 2017-08-30
ZA201506400B (en) 2020-12-23
KR20210122321A (ko) 2021-10-08
KR102554628B1 (ko) 2023-07-12
ZA202001372B (en) 2024-01-31
HRP20231522T1 (hr) 2024-03-01
DK3922241T3 (da) 2023-12-04
FI3922241T3 (fi) 2023-11-28
ES2877084T3 (es) 2021-11-16
US20160324780A1 (en) 2016-11-10
KR102310786B1 (ko) 2021-10-12
ES2964512T3 (es) 2024-04-08
SI3922241T1 (sl) 2024-03-29
US9737485B2 (en) 2017-08-22
EP2950784A2 (de) 2015-12-09
CN105163720B (zh) 2019-10-11
EP2950784A4 (de) 2016-11-09
EP4309657A2 (de) 2024-01-24
WO2014121211A3 (en) 2015-01-08
US20190110991A1 (en) 2019-04-18

Similar Documents

Publication Publication Date Title
ZA201506400B (en) Remote loading of sparingly water-soluble drugs into liposomes
ZA201702070B (en) Remote loading of sparingly water-soluble drugs into lipid vesicles
IL244259B (en) Insertion of medical devices
HK1219663A1 (zh) 藥物組合
EP4005604C0 (de) Verabreichung von arzneimitteln
GB201310263D0 (en) Burial capsule
EP2964261A4 (de) Stabilisierung von feuchtigkeitsempfindlichen arzneimitteln
GB201318686D0 (en) Pharmaceutical preparations
GB201419540D0 (en) Delivery of drugs
GB201308609D0 (en) Mixtures of haloalkysulfonanilide derivatives and herbicides
GB201301721D0 (en) Pharmaceutical Preparations
ZA201600027B (en) Pharmaceutical preparation
EP3060197C0 (de) Freisetzung von wirkstoffen anhand metastabiler liposomen
HK1204916A1 (en) Pharmaceutical application of anhydroicaritin
HK1220633A1 (zh) 含有氨基吡唑衍生物的藥物製劑
GB201308607D0 (en) Mixtures of haloalkylsulfonanilide derivatives and herbicides
GB201319437D0 (en) Delivery of drugs
ZA201506465B (en) Pharmaceutical preparation
PL3071575T3 (pl) Wytwarzanie normorfinanów
GB201322004D0 (en) Ground stabilisation
GB201319595D0 (en) Combination of Analgesic drugs
GB201316468D0 (en) Combination of analgesic drugs
GB201317726D0 (en) Fireworks igloo protector
GB201321316D0 (en) Pharmaceutical Compound
GB201309405D0 (en) Pharmaceutical compound